The promise of psychedelic research
Carina S Peritore
Future Drug Discovery February 18, 2022 DOI: 10.4155/fdd-2021-0012 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Psychedelics show potential for treating neuropsychiatric disorders and some neurodegenerative diseases by impacting brain structure and function. |
Abstract
The use of psychedelics as medicines and for overall better brain health is potentially one of the most transformative developments given their immediate and long-lasting therapeutic effects across a plethora of neuropsychiatric disorders and, more recently, some neurodegenerative diseases. The US psychedelic drugs market is forecasted to grow by 16.3% by 2027 due to the increasing prevalence of treatment-resistant depression and mental health disorders. Decades-long restrictions, which date back to when psychedelics were declared controlled substances in 1970, have been lifted to allow researchers to publish on the therapeutic benefits of psychedelics. This review will feature the incredible depth of research underway revealing how psychedelics impact brain structure and function to treat mental health and other neurological disorders.
Citations in the library
Cited by 2
Cites 45
- Synaptic Dysfunction in Depression: Potential Therapeutic Targets Science October 4, 2012
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
and 40 more in the library